Prostate cancer
About this PSP
The initial approach for this PSP came from the Prostate Cancer Research Foundation (now Prostate Cancer UK) and the Prostate Cancer Support Federation, supported by the Prostate Cancer Charter for Action.
An initial stakeholder meeting was held on 10 June 2009, which was attended by 26 participants, of which 20 represented organisations.
The Prostate Cancer PSP Top 10 was published in October 2010.
Key documents
Top 10 priorities
- How can overtreatment for prostate cancer be prevented by identifying and excluding the treatment of harmless tumours? (Tigers & Pussycats)
- Is there a genetic marker for prostate cancer that would be both more sensitive and more specific than PSA serum level?
- What can be done to delay or prevent the onset of hormone-independent prostate cancer?
- Are there any dietary measures that can prevent prostate cancer or slow its progression?
- Does serial PSA measurement in patients with prostate cancer accurately monitor disease progression?
- Would prostate cancer screening targeted at high risk groups, i.e. those with positive family history, and ethnic minorities with higher rates, improve the outcomes of treatment in these groups?
- Does active surveillance work for treatment of prostate cancer?
The following priorities were ranked joint 8th at the workshop:
- Do variations in GP awareness of prostate cancer affect outcomes?
- What is the effectiveness of new treatments for prostate cancer such as high intensity focused ultrasound and cryotherapy?
- Is there a vaccine that can prevent prostate cancer?
- Are there any non-intrusive diagnostic tests that will identify patients with aggressive prostate cancer whilst not identifying harmless cancers? (Tigers and Pussycats)
Document downloads
To see more uncertainties identified for Prostate Cancer see the document below